<ul>
<li>现在值得购买的三大医疗设备股票</li>
</ul>
<p>Bio-Rad Laboratories, Inc.（纽约证券交易所代码：BIO - 免费报告）- Zacks Research 在 9 月 22 日（星期一）发布的报告中下调了对 Bio-Rad Laboratories 2026 财年每股收益（EPS）的预期。Zacks Research 分析师团队现在预计该医疗研究公司将发布 10.36 美元的每股收益，低于之前预测的 10.43 美元。Zacks Research 对该股票给予了 “持有” 评级。市场普遍预计 Bio-Rad Laboratories 当前全年的每股收益为 10.81 美元。Zacks Research 还对 Bio-Rad Laboratories 2026 年第四季度的每股收益进行了预测，预计为 2.62 美元。</p>
<p>获取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
<p>BIO 在其他几份研究报告中也成为了话题。富国银行将 Bio-Rad Laboratories 的目标股价从 245.00 美元上调至 265.00 美元，并在 8 月 1 日（星期五）的报告中给予该股票 “等权重” 评级。加拿大皇家银行将 Bio-Rad Laboratories 的目标股价从 387.00 美元上调至 409.00 美元，并在 8 月 1 日（星期五）的研究报告中给予该股票 “跑赢大盘” 评级。最后，华尔街 Zen 在 8 月 22 日（星期五）的报告中将 Bio-Rad Laboratories 的评级从 “买入” 下调至 “持有”。三位分析师对该股票给予了 “买入” 评级，两位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 333.50 美元。</p>
<p><strong>阅读我们关于 BIO 的最新股票报告</strong></p>
<h2>Bio-Rad Laboratories 股票表现</h2>
<p>Bio-Rad Laboratories 的股票在星期二开盘价为 283.63 美元。Bio-Rad Laboratories 的 1 年最低价为 211.43 美元，1 年最高价为 387.99 美元。该公司的流动比率为 5.12，速动比率为 3.67，债务与股本比率为 0.17。该公司的市值为 76.8 亿美元，市盈率为 24.18，贝塔值为 0.95。该公司的 50 日简单移动平均线为 275.86 美元，200 日简单移动平均线为 252.83 美元。</p>
<p>Bio-Rad Laboratories（纽约证券交易所代码：BIO - 获取免费报告）最近于 7 月 31 日（星期四）公布了季度财报。该医疗研究公司报告的季度每股收益为 2.61 美元，超出分析师一致预期的 1.93 美元，超出幅度为 0.68 美元。该公司季度收入为 6.516 亿美元，而市场普遍预期为 6.1482 亿美元。Bio-Rad Laboratories 的净利润率为 12.50%，股本回报率为 4.01%。该公司季度收入同比增长 2.1%。在去年同期，该公司每股收益为 3.11 美元。Bio-Rad Laboratories 已设定 2025 财年的每股收益指导。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Nuveen Asset Management LLC 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 0.8%。Nuveen Asset Management LLC 目前拥有 39,505 股该医疗研究公司的股票，价值为 12,978,000 美元，在此期间又购买了 327 股。ProShare Advisors LLC 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 8.0%。ProShare Advisors LLC 目前拥有 901 股该医疗研究公司的股票，价值为 296,000 美元，在上个季度又收购了 67 股。Tidal Investments LLC 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 21.1%。Tidal Investments LLC 目前拥有 1,069 股该医疗研究公司的股票，价值为 351,000 美元，在上个季度又收购了 186 股。Two Sigma Investments LP 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 70.3%。Two Sigma Investments LP 目前拥有 2,050 股该医疗研究公司的股票，价值为 673,000 美元，在此期间又购买了 846 股。最后，俄亥俄州公共雇员退休系统在第四季度购买了 Bio-Rad Laboratories 的新股份，价值约为 2,211,000 美元。65.24% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Bio-Rad Laboratories</h2>
<p>（获取免费报告）</p>
<p>Bio-Rad Laboratories, Inc.在美国、欧洲、亚洲、加拿大和拉丁美洲制造和分销生命科学研究和临床诊断产品。它通过生命科学和临床诊断两个部门运营。该公司开发、制造和销售仪器、系统、试剂和耗材，以分离、纯化、表征和定量生物材料，如细胞、蛋白质和核酸，应用于蛋白质组学、基因组学、生物制药生产、细胞生物学和食品安全市场。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Bio-Rad Laboratories</li>
<li>如何投资 FAANG 股票</li>
<li>弱美元如何推动这些全球股票的上涨</li>
<li>如何计算期权利润</li>
<li>3 只在经济放缓时表现良好的股票</li>
<li>10 美元以下的最佳股票</li>
<li>3 只被低估的自动化股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bio-Rad Laboratories 吗？</h2>
<p>在你考虑 Bio-Rad Laboratories 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bio-Rad Laboratories 并不在名单上。</p>
<p>虽然 Bio-Rad 实验室目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Bio-Rad实验室-A

<p>Zacks Research 将 Bio-Rad Laboratories (NYSE:BIO) 的 2026 财年每股收益 (EPS) 预估从 $10.43 下调至 $10.36。该公司全年收益的当前共识预估为每股 $10.81。Zacks 对该股票维持 “持有” 评级，而富国银行和加拿大皇家银行则提高了其目标股价。Bio-Rad 的股票开盘价为 $283.63，市值为 76.8 亿美元，市盈率为 24.18。最近的季度收益超出预期，报告每股收益为 $2.61，超过共识预期的 $1.93</p>

<ul>
<li>The Top 3 Medical Devices Stocks to Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在值得购买的三大医疗设备股票</li>
</ul>
</div><p>Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research decreased their FY2026 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report released on Monday, September 22nd. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $10.36 for the year, down from their previous forecast of $10.43. Zacks Research has a &#34;Hold&#34; rating on the stock. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2026 earnings at $2.62 EPS.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories, Inc.（纽约证券交易所代码：BIO - 免费报告）- Zacks Research 在 9 月 22 日（星期一）发布的报告中下调了对 Bio-Rad Laboratories 2026 财年每股收益（EPS）的预期。Zacks Research 分析师团队现在预计该医疗研究公司将发布 10.36 美元的每股收益，低于之前预测的 10.43 美元。Zacks Research 对该股票给予了 “持有” 评级。市场普遍预计 Bio-Rad Laboratories 当前全年的每股收益为 10.81 美元。Zacks Research 还对 Bio-Rad Laboratories 2026 年第四季度的每股收益进行了预测，预计为 2.62 美元。</p>
</div><p>Get <strong>Bio-Rad Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
</div><p>BIO has been the topic of several other research reports. Wells Fargo &amp; Company upped their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, August 1st. Royal Bank Of Canada upped their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, August 1st. Finally, Wall Street Zen cut Bio-Rad Laboratories from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $333.50.</p>
<div class="lb-trans"><p>BIO 在其他几份研究报告中也成为了话题。富国银行将 Bio-Rad Laboratories 的目标股价从 245.00 美元上调至 265.00 美元，并在 8 月 1 日（星期五）的报告中给予该股票 “等权重” 评级。加拿大皇家银行将 Bio-Rad Laboratories 的目标股价从 387.00 美元上调至 409.00 美元，并在 8 月 1 日（星期五）的研究报告中给予该股票 “跑赢大盘” 评级。最后，华尔街 Zen 在 8 月 22 日（星期五）的报告中将 Bio-Rad Laboratories 的评级从 “买入” 下调至 “持有”。三位分析师对该股票给予了 “买入” 评级，两位分析师给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 333.50 美元。</p>
</div><p><strong>Read Our Latest Stock Report on BIO</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BIO 的最新股票报告</strong></p>
</div><h2>Bio-Rad Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>Bio-Rad Laboratories 股票表现</h2>
</div><p>Bio-Rad Laboratories stock opened at $283.63 on Tuesday. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $7.68 billion, a PE ratio of 24.18 and a beta of 0.95. The firm's 50 day simple moving average is $275.86 and its 200 day simple moving average is $252.83.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories 的股票在星期二开盘价为 283.63 美元。Bio-Rad Laboratories 的 1 年最低价为 211.43 美元，1 年最高价为 387.99 美元。该公司的流动比率为 5.12，速动比率为 3.67，债务与股本比率为 0.17。该公司的市值为 76.8 亿美元，市盈率为 24.18，贝塔值为 0.95。该公司的 50 日简单移动平均线为 275.86 美元，200 日简单移动平均线为 252.83 美元。</p>
</div><p>Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories（纽约证券交易所代码：BIO - 获取免费报告）最近于 7 月 31 日（星期四）公布了季度财报。该医疗研究公司报告的季度每股收益为 2.61 美元，超出分析师一致预期的 1.93 美元，超出幅度为 0.68 美元。该公司季度收入为 6.516 亿美元，而市场普遍预期为 6.1482 亿美元。Bio-Rad Laboratories 的净利润率为 12.50%，股本回报率为 4.01%。该公司季度收入同比增长 2.1%。在去年同期，该公司每股收益为 3.11 美元。Bio-Rad Laboratories 已设定 2025 财年的每股收益指导。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its position in Bio-Rad Laboratories by 0.8% during the 4th quarter. Nuveen Asset Management LLC now owns 39,505 shares of the medical research company's stock valued at $12,978,000 after buying an additional 327 shares during the period. ProShare Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 901 shares of the medical research company's stock valued at $296,000 after acquiring an additional 67 shares during the last quarter. Tidal Investments LLC raised its stake in shares of Bio-Rad Laboratories by 21.1% during the fourth quarter. Tidal Investments LLC now owns 1,069 shares of the medical research company's stock valued at $351,000 after acquiring an additional 186 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Bio-Rad Laboratories by 70.3% during the fourth quarter. Two Sigma Investments LP now owns 2,050 shares of the medical research company's stock worth $673,000 after purchasing an additional 846 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $2,211,000. 65.24% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Nuveen Asset Management LLC 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 0.8%。Nuveen Asset Management LLC 目前拥有 39,505 股该医疗研究公司的股票，价值为 12,978,000 美元，在此期间又购买了 327 股。ProShare Advisors LLC 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 8.0%。ProShare Advisors LLC 目前拥有 901 股该医疗研究公司的股票，价值为 296,000 美元，在上个季度又收购了 67 股。Tidal Investments LLC 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 21.1%。Tidal Investments LLC 目前拥有 1,069 股该医疗研究公司的股票，价值为 351,000 美元，在上个季度又收购了 186 股。Two Sigma Investments LP 在第四季度将其在 Bio-Rad Laboratories 的持仓增加了 70.3%。Two Sigma Investments LP 目前拥有 2,050 股该医疗研究公司的股票，价值为 673,000 美元，在此期间又购买了 846 股。最后，俄亥俄州公共雇员退休系统在第四季度购买了 Bio-Rad Laboratories 的新股份，价值约为 2,211,000 美元。65.24% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Bio-Rad Laboratories</h2>
<div class="lb-trans"><h2>关于 Bio-Rad Laboratories</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories, Inc.在美国、欧洲、亚洲、加拿大和拉丁美洲制造和分销生命科学研究和临床诊断产品。它通过生命科学和临床诊断两个部门运营。该公司开发、制造和销售仪器、系统、试剂和耗材，以分离、纯化、表征和定量生物材料，如细胞、蛋白质和核酸，应用于蛋白质组学、基因组学、生物制药生产、细胞生物学和食品安全市场。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Bio-Rad Laboratories</li>
<li>How to Invest in the FAANG Stocks</li>
<li>How The Weak Dollar Is Fueling These Global Stock Surges</li>
<li>How to Calculate Options Profits</li>
<li>3 Recession-Ready Stocks That Thrive When the Economy Sputters</li>
<li>Best Stocks Under $10.00</li>
<li>3 Automation-Focused Stocks Flying Under the Radar</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Bio-Rad Laboratories</li>
<li>如何投资 FAANG 股票</li>
<li>弱美元如何推动这些全球股票的上涨</li>
<li>如何计算期权利润</li>
<li>3 只在经济放缓时表现良好的股票</li>
<li>10 美元以下的最佳股票</li>
<li>3 只被低估的自动化股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Rad Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bio-Rad Laboratories 吗？</h2>
</div><p>Before you consider Bio-Rad Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bio-Rad Laboratories 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bio-Rad Laboratories 并不在名单上。</p>
</div><p>While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bio-Rad 实验室目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Zacks 研究对 Bio-Rad Lab 2026 财年收益的预测是什么？